Accretion Pharmaceuticals Share Price
200.00-2.00 (-0.99%)
+220.77% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 56% |
| - | - | - | 42% |
| - | - | - | 224% |
| 41% | 41% | 41% | 29% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
ACCPL-ST
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,899.7 | ₹456833 Cr | 37.77 | 12.07 | 62.82 | ₹11479 Cr |
| 9,148 | ₹245426 Cr | 83.91 | 34.04 | 128.41 | ₹2568 Cr |
| 4,829.5 | ₹187320 Cr | 85.89 | 16.72 | 97.06 | ₹2163 Cr |
| 1,128 | ₹113217 Cr | 25.09 | 9.42 | 62.53 | ₹5040 Cr |
| 1,381.4 | ₹112212 Cr | 33.29 | 9.77 | 57.87 | ₹3879 Cr |
| 1,846.3 | ₹101155 Cr | 92.52 | 6.8 | 29.25 | ₹889 Cr |
| 2,109.4 | ₹97626 Cr | 17.66 | 30.95 | 154.36 | ₹5333 Cr |
| 2,329.9 | ₹96859 Cr | 47.42 | 13.75 | 71.08 | ₹1913 Cr |
| 1,157.4 | ₹96406 Cr | 29.92 | 5.32 | 63.99 | ₹4196 Cr |
| 1,652.3 | ₹93614 Cr | 25.22 | 17.95 | 96.84 | ₹3505 Cr |
| 200 | ₹225 Cr | 23.23 | — | 9.79 | ₹10 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| — | — | — |
| ₹11 Cr | ₹8 Cr | ₹4 Cr |
| ₹44 Cr | ₹7 Cr | ₹1 Cr |
| ₹44 Cr | ₹7 Cr | ₹1 Cr |
| ₹55 Cr | ₹15 Cr | ₹5 Cr |
| ₹0 | ₹23 L | ₹1 Cr |
| ₹86 L | ₹94 L | ₹6 Cr |
| ₹27 L | ₹19 L | ₹14,000 |
| ₹1 Cr | ₹1 Cr | ₹7 Cr |
| — | — | — |
| ₹6 Cr | ₹8 Cr | ₹7 Cr |
| ₹3 Cr | ₹4 Cr | ₹2 Cr |
| ₹9 Cr | ₹9 Cr | ₹4 Cr |
| ₹4 Cr | ₹3 Cr | ₹2 Cr |
| ₹21 Cr | ₹23 Cr | ₹15 Cr |
| ₹77 Cr | ₹40 Cr | ₹27 Cr |
| ₹12 Cr | ₹14 Cr | ₹13 Cr |
| — | — | — |
| ₹15 Cr | ₹7 Cr | ₹5 Cr |
| ₹2 Cr | ₹100 L | ₹22 L |
| ₹13 Cr | ₹6 Cr | ₹5 Cr |
| ₹20 L | ₹0 | ₹0 |
| ₹31 L | ₹23 L | ₹0 |
| ₹0 | ₹66,000 | ₹13 L |
| ₹14 Cr | ₹6 Cr | ₹5 Cr |
| — | — | — |
| ₹28 Cr | ₹21 Cr | ₹14 Cr |
| ₹22 Cr | ₹12 Cr | ₹6 Cr |
| ₹4 Cr | ₹5 L | ₹9 L |
| ₹2 L | ₹2 L | ₹6 L |
| ₹6 Cr | ₹1 Cr | ₹2 Cr |
| ₹60 Cr | ₹33 Cr | ₹22 Cr |
| ₹40 Cr | ₹10 Cr | ₹7 Cr |
| ₹3 Cr | ₹10 L | ₹0 |
| ₹77 Cr | ₹40 Cr | ₹27 Cr |
| ₹47 | ₹19 | ₹14 |
| ₹47 | ₹19 | ₹7 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|
| ₹13 Cr | ₹10 Cr | ₹2 Cr |
| ₹2 Cr | ₹2 Cr | ₹62 L |
| -₹26 Cr | -₹10 Cr | -₹15 Cr |
| -₹11 Cr | ₹2 Cr | -₹12 Cr |
| -₹15 Cr | -₹62 L | -₹12 Cr |
| -₹9 Cr | -₹2 Cr | -₹5 Cr |
| ₹27 Cr | ₹2 Cr | ₹17 Cr |
| ₹4 Cr | -₹4 L | ₹9 L |
| ₹5 L | ₹9 L | ₹0 |
| ₹4 Cr | ₹5 L | ₹9 L |
Fundamental Ratios
Consolidated
Standalone
No results found